E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib
Akihiko Miyanaga(Nippon Medical School), Shoji Kudoh(Japan Anti Tuberculosis Association)
Cited by 17
Related Papers
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953
Interstitial Lung Disease in Japanese Patients with Lung Cancer
|American Journal of Respiratory and Critical Care Medicine|2008|488
Serological Diagnosis of Idiopathic Pulmonary Alveolar Proteinosis
|American Journal of Respiratory and Critical Care Medicine|2000|226
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
|British Journal of Cancer|2005|135
PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors
|International Journal of Oncology|2007|53